EA200300628A1 - CONNECTIONS SPECIFIC TO Adenosine A, A And Arecceptor, And Their Use - Google Patents
CONNECTIONS SPECIFIC TO Adenosine A, A And Arecceptor, And Their UseInfo
- Publication number
- EA200300628A1 EA200300628A1 EA200300628A EA200300628A EA200300628A1 EA 200300628 A1 EA200300628 A1 EA 200300628A1 EA 200300628 A EA200300628 A EA 200300628A EA 200300628 A EA200300628 A EA 200300628A EA 200300628 A1 EA200300628 A1 EA 200300628A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- adenosine
- arecceptor
- compounds
- connections specific
- receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Abstract
Данное изобретение относится к соединениям, которые специфически ингибируют A, Aи Aрецепторы, и применению данных соединений для лечения заболеваний, связанных с A, Aи Aаденозиновыми рецепторами, у субъектов, включающему введение субъекту терапевтически эффективного количества соединений.Международная заявка была опубликована вместе с отчетом о международном поиске.This invention relates to compounds that specifically inhibit A, A, and A receptors, and the use of these compounds to treat diseases associated with A, A, and Adenosine receptors in subjects, including administering to the subject a therapeutically effective amount of compounds. The international application has been published search.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/728,616 US7160890B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A3 receptor and uses thereof |
US09/728,607 US6664252B2 (en) | 1999-12-02 | 2000-12-01 | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
US09/728,316 US6680322B2 (en) | 1999-12-02 | 2000-12-01 | Compounds specific to adenosine A1 receptors and uses thereof |
PCT/US2001/045280 WO2002057267A1 (en) | 2000-12-01 | 2001-11-30 | Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200300628A1 true EA200300628A1 (en) | 2003-12-25 |
EA007254B1 EA007254B1 (en) | 2006-08-25 |
Family
ID=27419112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200300628A EA007254B1 (en) | 2000-12-01 | 2001-11-30 | Compounds specific to adenosine a, aand areceptor and uses thereof |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1347980A4 (en) |
JP (1) | JP4579497B2 (en) |
CN (1) | CN1263757C (en) |
AP (1) | AP1893A (en) |
AU (1) | AU2002248151B2 (en) |
BR (1) | BR0115847A (en) |
CA (1) | CA2430577A1 (en) |
CZ (1) | CZ20031831A3 (en) |
EA (1) | EA007254B1 (en) |
HU (1) | HUP0400692A3 (en) |
IL (1) | IL155962A0 (en) |
ME (1) | MEP35308A (en) |
MX (1) | MXPA03004717A (en) |
NO (1) | NO327207B1 (en) |
NZ (1) | NZ525885A (en) |
OA (1) | OA13295A (en) |
PL (1) | PL363245A1 (en) |
WO (1) | WO2002057267A1 (en) |
YU (1) | YU42703A (en) |
ZA (1) | ZA200303729B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5090531A (en) * | 1990-01-10 | 1992-02-25 | Lord Corporation | Electrophoretic fluid differential |
ID27600A (en) | 1998-06-02 | 2001-04-12 | Osi Pharm Inc | PIROLO COMPOSITION (2,3d) PYRIMIDINE AND ITS USE |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
DE10148883A1 (en) * | 2001-10-04 | 2003-04-10 | Merck Patent Gmbh | New fused bi- or tricyclic pyrimidine derivatives, are phosphodiesterase V inhibitors useful e.g. for treating impotence, cardiovascular disorders, inflammation or tumors |
US7504407B2 (en) | 2001-11-30 | 2009-03-17 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 and A3 receptors and uses thereof |
CA2469316A1 (en) * | 2001-12-07 | 2003-06-19 | Vertex Pharmaceuticals, Inc. | Pyrimidine-based compounds useful as gsk-3 inhibitors |
CN1816551A (en) | 2001-12-20 | 2006-08-09 | Osi药物公司 | Pyrrolopyrimidine a2b selective antagonist compounds, their synthesis and use |
EA007468B1 (en) | 2001-12-20 | 2006-10-27 | Оси Фармасьютикалз, Инк. | Pyrimidine a2b selective antagonist compounds, their synthesis and use |
CA2502429A1 (en) * | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
HUP0203976A3 (en) * | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
UY29177A1 (en) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES |
ES2878130T3 (en) | 2006-04-25 | 2021-11-18 | Astex Therapeutics Ltd | Derivatives of purine and deazapurine as pharmaceutical compounds |
US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
TW200808819A (en) * | 2006-06-19 | 2008-02-16 | Solvay Pharm Gmbh | Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty |
MY150059A (en) | 2007-10-11 | 2013-11-29 | Astrazeneca Ab | Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors |
AR070127A1 (en) | 2008-01-11 | 2010-03-17 | Novartis Ag | PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS |
NZ586642A (en) | 2008-01-11 | 2012-04-27 | Natco Pharma Ltd | Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents |
SI2694056T1 (en) | 2011-04-01 | 2019-12-31 | Astrazeneca Ab | Therapeutic treatment |
PT2785349T (en) | 2011-11-30 | 2019-12-11 | Astrazeneca Ab | Combination treatment of cancer |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
MX2014014832A (en) * | 2012-06-07 | 2015-02-12 | Hoffmann La Roche | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase. |
EP3010917B1 (en) * | 2013-06-21 | 2018-01-31 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
SG11201510409QA (en) | 2013-06-21 | 2016-01-28 | Zenith Epigenetics Corp | Novel bicyclic bromodomain inhibitors |
JP6542212B2 (en) | 2013-07-31 | 2019-07-10 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | Novel quinazolinones as bromodomain inhibitors |
CA2966298A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
JP2017538721A (en) | 2014-12-17 | 2017-12-28 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | Bromodomain inhibitors |
PL3248980T3 (en) * | 2015-01-20 | 2024-03-04 | Wuxi Fortune Pharmaceutical Co., Ltd | Jak inhibitor |
TR201909694T4 (en) | 2015-04-29 | 2019-07-22 | Wuxi Fortune Pharmaceutical Co Ltd | Janus kinase (jack) inhibitors. |
JP6564473B2 (en) | 2015-05-29 | 2019-08-21 | 无▲錫▼福祈制▲薬▼有限公司Wuxi Fortune Pharmaceutical Co.,Ltd | Janus kinase inhibitor |
CN105771672B (en) * | 2016-04-18 | 2018-03-02 | 天津工业大学 | A kind of antipollution antibiotic aromatic polyamide reverse osmosis composite film and preparation method |
EP3594216B1 (en) * | 2017-03-07 | 2022-04-06 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof |
CN108017584B (en) * | 2017-06-20 | 2021-03-23 | 南开大学 | A3Small molecule antagonists of adenosine receptors |
AU2019282098B2 (en) * | 2018-06-04 | 2023-12-14 | Evotec International Gmbh | Pyrazolopyrimidine compounds as adenosine receptor antagonists |
CN110128316B (en) * | 2019-05-22 | 2021-08-31 | 北京大学深圳研究生院 | Preparation method of 5-substituted beta-proline and derivatives thereof |
CN110272373B (en) * | 2019-07-02 | 2022-07-29 | 天津国际生物医药联合研究院 | Selective adenosine A 1 Receptor antagonists and uses thereof |
CN114085178A (en) * | 2021-12-29 | 2022-02-25 | 苏州楚凯药业有限公司 | Preparation method of 4-methyl-1-propyl-2-amino-1H-pyrrole-3-nitrile |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2128544T3 (en) * | 1992-12-17 | 1999-05-16 | Pfizer | PYROLOPYRIMIDINES AS CRF ANTAGONISTS. |
US5780450A (en) * | 1995-11-21 | 1998-07-14 | Alcon Laboratories, Inc. | Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage |
ID27600A (en) * | 1998-06-02 | 2001-04-12 | Osi Pharm Inc | PIROLO COMPOSITION (2,3d) PYRIMIDINE AND ITS USE |
EP1731520A1 (en) * | 1999-12-02 | 2006-12-13 | OSI Pharmaceuticals, Inc. | Pyrrolo[2,3-d]pyrimidine derivatives which are antagonists of adenosine A1, A2A, and A3 |
US7504407B2 (en) * | 2001-11-30 | 2009-03-17 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 and A3 receptors and uses thereof |
-
2001
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en active IP Right Grant
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/en unknown
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/en active IP Right Grant
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 YU YU42703A patent/YU42703A/en unknown
- 2001-11-30 CN CNB018224601A patent/CN1263757C/en not_active Expired - Fee Related
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/en unknown
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/en unknown
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/en not_active Application Discontinuation
- 2001-11-30 EA EA200300628A patent/EA007254B1/en not_active IP Right Cessation
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/en not_active Expired - Fee Related
- 2001-11-30 IL IL15596201A patent/IL155962A0/en unknown
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 PL PL01363245A patent/PL363245A1/en not_active Application Discontinuation
-
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ZA200303729B (en) | 2004-05-14 |
YU42703A (en) | 2006-03-03 |
EP1347980A1 (en) | 2003-10-01 |
JP2004517896A (en) | 2004-06-17 |
NO20032482L (en) | 2003-07-28 |
BR0115847A (en) | 2004-02-25 |
WO2002057267A1 (en) | 2002-07-25 |
MXPA03004717A (en) | 2004-06-30 |
AU2002248151B2 (en) | 2008-02-21 |
OA13295A (en) | 2007-04-13 |
NZ525885A (en) | 2005-01-28 |
JP4579497B2 (en) | 2010-11-10 |
NO327207B1 (en) | 2009-05-11 |
AP2003002807A0 (en) | 2003-06-30 |
MEP35308A (en) | 2011-02-10 |
CZ20031831A3 (en) | 2004-05-12 |
HUP0400692A3 (en) | 2007-09-28 |
CA2430577A1 (en) | 2002-07-25 |
EP1347980A4 (en) | 2005-02-09 |
CN1263757C (en) | 2006-07-12 |
PL363245A1 (en) | 2004-11-15 |
NO20032482D0 (en) | 2003-06-02 |
EA007254B1 (en) | 2006-08-25 |
IL155962A0 (en) | 2003-12-23 |
AP1893A (en) | 2008-09-23 |
CN1489590A (en) | 2004-04-14 |
HUP0400692A2 (en) | 2004-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200300628A1 (en) | CONNECTIONS SPECIFIC TO Adenosine A, A And Arecceptor, And Their Use | |
EA200100780A1 (en) | TWEAK ANTAGONISTS AND TWEAK RECEPTORS AND THEIR USE FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES | |
DK1450811T3 (en) | Compounds specific for adenosine A1 and A3 receptors and uses thereof | |
WO2001039777A8 (en) | Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof | |
EA200300293A1 (en) | ANTI-INFLAMMATORY CONDENSED Pyrrolocarbazoles | |
DK1346041T3 (en) | Therapeutic agents and methods for their use in the treatment of an amyloidogenic disease | |
CY1105082T1 (en) | USE OF FLIVANSEPIN IN THE TREATMENT OF SEXUAL DESIRE DISORDERS | |
EA200601776A1 (en) | METADONIC COMPOSITIONS OF LOCAL ACTION AND METHODS OF THEIR APPLICATION | |
EA200500520A1 (en) | PURINE COMPOUNDS AND THEIR APPLICATION AS CANCELINOID RECEPTOR LIGANDS AS LIGANDS | |
CY1112858T1 (en) | THERAPEUTIC HUMAN ANTI-IL-1R1 MONOCLONE ANTIBODY | |
CY1113489T1 (en) | ANTIBODY THAT INCLUDES ALPHABETA7 INTEGRINE AND USE THIS IN THE THERAPEUTIC TREATMENT OF THE INFLAMMATORY INTELLIGENCE | |
BRPI0411677A (en) | methods of using heterocyclic compounds [3.2.0] and their analogues | |
TR200103233T2 (en) | New drug compositions on the basis of anticholinergic compounds and ß-mimetics. | |
BG66080B1 (en) | Substituted thioacetamides | |
EA200200616A1 (en) | CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENT | |
CY1106845T1 (en) | USE OF FLUMAZENIL FOR THE PREPARATION OF A DRUG FOR THE TREATMENT OF COCAINE DEPENDENCE | |
ATE371645T1 (en) | NAPHTHALINE DERIVATIVES THAT BIND TO THE EP4 RECEPTOR | |
CY1108430T1 (en) | USE OF NETHERLANDS SIDE BASKET COMPETITORS WITH AMITERASE FOR ECOPARATOMETER CONTROLS IN HOUSEHOLD ANIMALS | |
EA200401341A1 (en) | APPLICATION OF OSTEOPROTEGERIN FOR THE TREATMENT AND / OR PREVENTION OF FIBROUS DISEASE | |
EA200700407A1 (en) | HINAZOLIN DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOCYTHEMIA | |
EE200200107A (en) | Use of a fast-acting selective serotonin reuptake inhibitor in the manufacture of a medicament for the treatment of sexual dysfunction | |
BRPI0409359A (en) | somatostatin-dopamine chimeric analogs | |
TR199802769T2 (en) | Topical composition containing a combination of terpenoid compounds and antihistamine compounds. | |
TR200001040T2 (en) | A new use of compounds for an anti-itch effect | |
EA200400399A1 (en) | METHODS OF TREATMENT OF PULMONARY DISEASES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |